NZ713080A - Pyridin-4-yl derivatives - Google Patents

Pyridin-4-yl derivatives

Info

Publication number
NZ713080A
NZ713080A NZ713080A NZ71308014A NZ713080A NZ 713080 A NZ713080 A NZ 713080A NZ 713080 A NZ713080 A NZ 713080A NZ 71308014 A NZ71308014 A NZ 71308014A NZ 713080 A NZ713080 A NZ 713080A
Authority
NZ
New Zealand
Prior art keywords
derivatives
pyridin
receptor
diseases
prevention
Prior art date
Application number
NZ713080A
Other languages
English (en)
Inventor
Martin Bolli
Cyrille Lescop
Oliver Nayler
Beat Steiner
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of NZ713080A publication Critical patent/NZ713080A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
NZ713080A 2013-03-15 2014-03-14 Pyridin-4-yl derivatives NZ713080A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13159482 2013-03-15
PCT/IB2014/059794 WO2014141171A1 (en) 2013-03-15 2014-03-14 Pyridin-4-yl derivatives

Publications (1)

Publication Number Publication Date
NZ713080A true NZ713080A (en) 2020-06-26

Family

ID=47877933

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ713080A NZ713080A (en) 2013-03-15 2014-03-14 Pyridin-4-yl derivatives

Country Status (33)

Country Link
US (1) US9617250B2 (cg-RX-API-DMAC7.html)
EP (1) EP2970236B1 (cg-RX-API-DMAC7.html)
JP (1) JP6387361B2 (cg-RX-API-DMAC7.html)
KR (1) KR102212975B1 (cg-RX-API-DMAC7.html)
CN (1) CN105189487B (cg-RX-API-DMAC7.html)
AR (1) AR095523A1 (cg-RX-API-DMAC7.html)
AU (1) AU2014229217B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015023161B1 (cg-RX-API-DMAC7.html)
CA (1) CA2900910C (cg-RX-API-DMAC7.html)
CL (1) CL2015002620A1 (cg-RX-API-DMAC7.html)
CY (1) CY1119619T1 (cg-RX-API-DMAC7.html)
DK (1) DK2970236T3 (cg-RX-API-DMAC7.html)
EA (1) EA029309B1 (cg-RX-API-DMAC7.html)
ES (1) ES2649475T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20171763T1 (cg-RX-API-DMAC7.html)
HU (1) HUE035154T2 (cg-RX-API-DMAC7.html)
IL (1) IL241363B (cg-RX-API-DMAC7.html)
LT (1) LT2970236T (cg-RX-API-DMAC7.html)
MA (1) MA38482B1 (cg-RX-API-DMAC7.html)
MX (1) MX363545B (cg-RX-API-DMAC7.html)
MY (1) MY173573A (cg-RX-API-DMAC7.html)
NO (1) NO2970236T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ713080A (cg-RX-API-DMAC7.html)
PH (1) PH12015502118A1 (cg-RX-API-DMAC7.html)
PL (1) PL2970236T3 (cg-RX-API-DMAC7.html)
PT (1) PT2970236T (cg-RX-API-DMAC7.html)
SA (1) SA515361104B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201507227UA (cg-RX-API-DMAC7.html)
SI (1) SI2970236T1 (cg-RX-API-DMAC7.html)
TW (1) TWI623534B (cg-RX-API-DMAC7.html)
UA (1) UA115357C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014141171A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201507657B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014110574A1 (en) 2013-01-14 2014-07-17 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
UA121098C2 (uk) 2013-01-15 2020-04-10 Інсайт Холдинґс Корпорейшн Тіазолкарбоксаміди і піридинкарбоксаміди, які використовуються як інгібітори рім-кінази
WO2015027124A1 (en) 2013-08-23 2015-02-26 Incyte Corporation Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
ES2770348T3 (es) 2015-05-20 2020-07-01 Idorsia Pharmaceuticals Ltd Forma cristalina del compuesto (s)-3-{4-[5-(2-ciclopentil-6-metoxi-piridin-4-il)-[1,2,4]oxadiazol-3-il]-2-etil-6-metil-fenoxi}-propano-1,2-diol
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
WO2017004610A1 (en) * 2015-07-02 2017-01-05 Exelixis, Inc. Tercyclic s1p3-sparing, s1p1 receptor agonists
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
WO2017059251A1 (en) 2015-10-02 2017-04-06 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7686891A (en) 1990-04-05 1991-10-30 American National Red Cross, The A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
WO1999046277A1 (en) 1998-03-09 1999-09-16 Smithkline Beecham Corporation HUMAN EDG-1c POLYNUCLEOTIDES AND POLYPEPTIDES AND METHODS OF USE
AU2003279915A1 (en) 2002-10-15 2004-05-04 Merck And Co., Inc. Process for making azetidine-3-carboxylic acid
SI2069336T1 (sl) * 2006-09-07 2013-03-29 Actelion Pharmaceuticals Ltd. Derivati piridin-4-ila kot imunomodulirna sredstva
CL2007002594A1 (es) 2006-09-08 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. .
KR20090051774A (ko) 2006-09-21 2009-05-22 액테리온 파마슈티칼 리미티드 페닐 유도체 및 면역조절제로서 이들의 용도
AU2008227979B2 (en) 2007-03-16 2014-02-06 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as S1P1 /EDG1 receptor agonists
MX2010001881A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de piridina como moduladores del receptor s1p1/edg1.
KR20100075608A (ko) 2007-10-04 2010-07-02 메르크 세로노 에스. 에이. 옥사다이졸 유도체
ES2449749T3 (es) 2007-11-01 2014-03-21 Actelion Pharmaceuticals Ltd. Nuevos derivados de pirimidina
JP5411877B2 (ja) 2008-03-06 2014-02-12 アクテリオン ファーマシューティカルズ リミテッド ピリジン化合物
US20110046170A1 (en) 2008-03-06 2011-02-24 Martin Bolli Novel pyrimidine-pyridine derivatives
HRP20130641T1 (en) 2008-03-07 2013-08-31 Actelion Pharmaceuticals Ltd. Pyridin-2-yl derivatives as immunomodulating agents
RU2010140847A (ru) 2008-03-07 2012-04-20 Актелион Фармасьютиклз Лтд (Ch) Новые производные аминометилбензола
MY156381A (en) * 2008-05-14 2016-02-15 Scripps Research Inst Novel modulators of sphingosine phosphate receptors
CA2752804C (en) 2009-03-03 2017-04-04 Anna Quattropani Oxazole pyridine derivatives useful as s1p1 receptor agonists
MY153617A (en) 2009-07-16 2015-02-27 Actelion Pharmaceuticals Ltd Pyridin-4-yl derivatives
TW201120016A (en) 2009-12-08 2011-06-16 Abbott Lab Novel oxadiazole compounds
MX350009B (es) 2011-01-19 2017-08-23 Idorsia Pharmaceuticals Ltd Derivados de 2-metoxi-piridin-4-ilo.

Also Published As

Publication number Publication date
CY1119619T1 (el) 2018-04-04
DK2970236T3 (en) 2017-10-16
PL2970236T3 (pl) 2018-01-31
ES2649475T3 (es) 2018-01-12
KR102212975B1 (ko) 2021-02-05
PH12015502118B1 (en) 2016-01-25
US20160031866A1 (en) 2016-02-04
JP2016512227A (ja) 2016-04-25
HUE035154T2 (en) 2018-05-02
EA201500931A1 (ru) 2016-03-31
MY173573A (en) 2020-02-04
IL241363A0 (en) 2015-11-30
BR112015023161A8 (pt) 2021-06-22
CA2900910A1 (en) 2014-09-18
US9617250B2 (en) 2017-04-11
NO2970236T3 (cg-RX-API-DMAC7.html) 2018-01-27
AU2014229217A1 (en) 2015-11-05
AU2014229217B2 (en) 2017-12-14
CL2015002620A1 (es) 2016-03-18
EA029309B1 (ru) 2018-03-30
MX2015012293A (es) 2015-12-16
PH12015502118A1 (en) 2016-01-25
AR095523A1 (es) 2015-10-21
EP2970236A1 (en) 2016-01-20
CN105189487A (zh) 2015-12-23
IL241363B (en) 2018-11-29
LT2970236T (lt) 2017-11-10
HK1220454A1 (en) 2017-05-05
SA515361104B1 (ar) 2016-06-28
CN105189487B (zh) 2017-12-26
TW201443044A (zh) 2014-11-16
MA38482A1 (fr) 2017-12-29
EP2970236B1 (en) 2017-08-30
WO2014141171A1 (en) 2014-09-18
UA115357C2 (uk) 2017-10-25
MX363545B (es) 2019-03-27
CA2900910C (en) 2021-03-30
BR112015023161B1 (pt) 2022-11-16
JP6387361B2 (ja) 2018-09-05
KR20150128947A (ko) 2015-11-18
ZA201507657B (en) 2022-08-31
BR112015023161A2 (pt) 2017-07-18
HRP20171763T1 (hr) 2017-12-29
SG11201507227UA (en) 2015-10-29
TWI623534B (zh) 2018-05-11
MA38482B1 (fr) 2018-11-30
SI2970236T1 (sl) 2017-11-30
PT2970236T (pt) 2017-11-30

Similar Documents

Publication Publication Date Title
NZ713080A (en) Pyridin-4-yl derivatives
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MD20170020A2 (ro) Compoziţii şi metode utilizate pentru tratamentul tulburărilor metabolice
EA201591612A1 (ru) ПРИМЕНЕНИЕ ПИРАЗОЛПИРИМИДИНОВЫХ ПРОИЗВОДНЫХ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, СВЯЗАННЫХ С PI3Kδ
WO2014042433A3 (en) Compounds and compositions for modulating adenosine a3 receptor activity
MX2015016741A (es) Inhibidores de pi3 cinasa delta y gama selectivos duales.
PH12016502291A1 (en) Indolizine derivatives as phosphoinositide 3-kinases inhibitors
IL244182A0 (en) Preparations, methods and systems for the treatment of skin disorders
PH12016501160A1 (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
WO2013185048A3 (en) Heterocyclic guanidine f1f0-atpase inhibitors
MX2016007445A (es) Inhibidores de f1f0-atpasa de trifluorometil pirazolil guanidina y usos terapeuticos de los mismos.
GEP20196984B (en) Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder
TN2016000107A1 (en) Substituted phenylalanine derivatives
MX2016016491A (es) Derivados de o-alquil-bencilidenguanidina y uso terapeutico para el tratamiento de trastornos asociados con acumulacion de proteinas mal plegadas.
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
MX2020011766A (es) Metodos de administracion de tratamiento antifibrotico.
PH12016501127A1 (en) Adenosine a1 agonists as medicaments against renal diseases
MX2016013979A (es) Nuevas vias de administracion de insulina, analogos de insulina o derivados de insulina.
MX355103B (es) Composicion para el tratamiento de desordenes inflamatorios e inmunes.
JO3621B1 (ar) مركبات وتركيبات على هيئة عوامل مساعدة لمستقبل 7 يشبه toll
GB201413533D0 (en) Combination therapy for treating disorders of the vestibular system

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: IDORSIA PHARMACEUTICALS LTD, CH

Effective date: 20171005

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2022 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20210302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2023 BY PETRA OLK

Effective date: 20220307

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 MAR 2024 BY DENNEMEYER + CO.

Effective date: 20230307

LAPS Patent lapsed